Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.86% | -10.07% | -21.67% | -46.33% | -53.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.86% | -10.07% | -21.67% | -46.33% | -53.10% |
| Cost of Revenue | 12.27% | -15.70% | 56.45% | -58.16% | -27.75% |
| Gross Profit | 94.03% | -7.58% | -38.52% | -35.22% | -65.86% |
| SG&A Expenses | 26.54% | 13.46% | -9.01% | 2.77% | -34.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.05% | 9.08% | -3.73% | -11.29% | -33.54% |
| Operating Income | -18.46% | -27.60% | -11.46% | -20.41% | 25.93% |
| Income Before Tax | -229.09% | 5.02% | 6.39% | -31.48% | 27.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -229.09% | 5.02% | 6.39% | -31.48% | 27.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -229.09% | 5.02% | 6.39% | -31.48% | 27.96% |
| EBIT | -18.46% | -27.60% | -11.46% | -20.41% | 25.93% |
| EBITDA | -18.51% | -27.89% | -14.10% | -23.01% | 25.38% |
| EPS Basic | -100.00% | -- | -- | -- | 0.00% |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -100.00% | -- | -- | -- | 0.00% |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 0.44% | 1.50% | 0.57% | 0.79% | 0.61% |
| Average Diluted Shares Outstanding | 0.44% | 1.50% | 0.57% | 0.79% | 0.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |